Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2022-12-30 · accession 0001209191-23-000947 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-04 | 2022-12-30 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $5.35 | +23.7K | 61.2K | +63% | +$126.7K |
| D | 2023-01-04 | 2022-12-30 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $0.00 | -23.7K | 430.8K | -5% | $0 |
| D | 2023-01-04 | 2022-12-30 | PCVX | GUGGENHIME ANDREW | Pres, CFO | A - Grant | $0.00 | +42.0K | 42.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | M | A | 23,691 | $5.35 | 61,229 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-12-30 | M | D | 23,691 | $0.00 | 430,827 | D | $5.35 · — to 2030-05-11 | 23,691 Common Stock | (F2) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 3 | Derivative | Stock Option (right to buy) | 2022-12-30 | A | A | 42,000 | $0.00 | 42,000 | D | $47.95 · — to 2032-12-30 | 42,000 Common Stock | (F1) 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |